Compare GSK plc (GSK) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Skyworks Solutions Inc — how do they compare? GSK plc trades at $52.79 (market cap $101.34B), while Skyworks Solutions Inc trades at $56.34 (market cap $8.65B). The key difference: GSK plc is far larger — about 11.7× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.94%). Which is the better fit depends on your goals.
| GSK | SWKS | |
|---|---|---|
Market Cap | $101.34B | $8.65B |
Sector | Health | Technology |
52-Week High | $61.18 | $83.40 |
52-Week Low | $36.20 | $52.50 |
Enterprise Value | $121.95B | $8.42B |
Dividend Yield | 3.49% | 4.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Skyworks Solutions (SWKS) trades at $56.58, down 2.85% on the day, reflecting a bearish technical signal despite recent earnings beats. The stock shows a mixed picture with strong analyst consensus (58% buy rating) and a $72.56 price target suggesting 28% upside, but faces declining revenue and profit margins. Recent news highlights the company's strategic moves in EV and AI infrastructure markets, alongside ongoing legal investigations that create investor uncertainty.
The outlook balances significant upside potential from analyst targets and strategic diversification against clear risks: declining financial metrics, legal overhangs, and technical weakness. Investment opportunity exists for those believing in the company's market positioning and turnaround potential, but requires careful monitoring of revenue stabilization and resolution of legal matters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
